NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Price, News & Analysis $1.40 -0.06 (-3.77%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Inovio Pharmaceuticals Stock (NASDAQ:INO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inovio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.40▼$1.4550-Day Range$0.60▼$1.8952-Week Range$0.56▼$2.72Volume1.64 million shsAverage Volume4.87 million shsMarket Capitalization$154.80 millionP/E RatioN/ADividend YieldN/APrice Target$6.33Consensus RatingModerate Buy Company Overview Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells. The company’s work is primarily research and clinical development rather than the sale of a broad portfolio of commercial medicines. Founded in 1983 and formerly known as Inovio Biomedical Corporation, the company is headquartered in Plymouth Meeting, Pennsylvania. Its clinical programs and collaborations have involved research and development activities beyond the United States. Jacqueline Shea has served as Inovio’s president and chief executive officer.AI Generated. May Contain Errors. Read More Inovio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreINO MarketRank™: 3.14261371084 of 5 starsInovio Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 330th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingInovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInovio Pharmaceuticals has a consensus price target of $6.33, representing about 347.6% upside from its current price of $1.42.Amount of Analyst CoverageInovio Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inovio Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.74) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inovio Pharmaceuticals is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inovio Pharmaceuticals is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.41% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently increased by 3.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.42 News SentimentInovio Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Inovio Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest41 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 215% compared to the previous 30 days.MarketBeat Follows11 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by Institutions26.79% of the stock of Inovio Pharmaceuticals is held by institutions.Read more about Inovio Pharmaceuticals' insider trading history. Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INO Stock News HeadlinesInovio Pharmaceuticals (NASDAQ:INO) Stock Keeps "Buy" Rating at HC WainwrightNovember 13 at 3:55 AM | americanbankingnews.comInovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12 at 9:36 AM | marketscreener.comMMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlights: FDA Approval, Commercial ...November 12 at 9:36 AM | finance.yahoo.comINOVIO to Participate in Upcoming Investor ConferencesNovember 11 at 12:42 PM | finance.yahoo.comINOVIO to Participate in Upcoming Investor ConferencesNovember 11 at 8:05 AM | prnewswire.comInovio Pharmaceuticals, Inc. (INO) Q3 2026 Earnings Call TranscriptNovember 11 at 1:17 AM | seekingalpha.comInovio outlines late Q4 2027 cash runway as it targets VOCERYQ launch and Europe filing by year-end 2026November 11 at 1:17 AM | seekingalpha.comSee More Headlines INO Stock Analysis - Frequently Asked Questions How have INO shares performed this year? Inovio Pharmaceuticals' stock was trading at $1.74 at the start of the year. Since then, INO stock has decreased by 18.7% and is now trading at $1.4150. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.29. The biopharmaceutical company earned $298.90 thousand during the quarter, compared to the consensus estimate of $2.27 million. Read the conference call transcript. When did Inovio Pharmaceuticals' stock split? Inovio Pharmaceuticals shares reverse split before market open on Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' top institutional investors include State Street Corp (0.32%), Green Alpha Advisors LLC (0.11%), LexAurum Advisors LLC (0.09%) and Prime Capital Investment Advisors LLC (0.07%). View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include Moderna (MRNA), Tesla (tsla), Novavax (NVAX), Advanced Micro Devices (AMD), NVIDIA (NVDA), NIO (NIO) and Gilead Sciences (GILD). Company Calendar Last Earnings11/10/2026Today11/13/2026Jefferies Global Healthcare Conference11/18/202638th Annual Healthcare Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 11 days, INO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INO CIK1055726 Webwww.inovio.com Phone(858) 410-3134Fax267-440-4242Employees112Year Founded1979Price Target and Rating Average Price Target for Inovio Pharmaceuticals$6.33 High Price Target$8.00 Low Price Target$5.00 Potential Upside/Downside+347.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.95 million Net MarginsN/A Pretax Margin-23,790.97% Return on Equity-28,886.30% Return on Assets-75.67% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio1.00 Sales & Book Value Annual Sales$60 thousand Price / Sales2,598.41 Cash FlowN/A Price / Cash FlowN/A Book Value($0.31) per share Price / Book-4.56Miscellaneous Outstanding Shares110,180,000Free Float108,309,000Market Cap$155.90 million OptionableOptionable Beta1.71 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:INO) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
